KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biomarin Pharmaceutical (BMRN) EBIT (2017 - 2025)

Historic EBIT for Biomarin Pharmaceutical (BMRN) over the last 16 years, with Q3 2025 value amounting to -$46.7 million.

  • Biomarin Pharmaceutical's EBIT fell 14099.64% to -$46.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $615.5 million, marking a year-over-year increase of 7581.25%. This contributed to the annual value of $484.2 million for FY2024, which is 16064.68% up from last year.
  • As of Q3 2025, Biomarin Pharmaceutical's EBIT stood at -$46.7 million, which was down 14099.64% from $276.9 million recorded in Q2 2025.
  • In the past 5 years, Biomarin Pharmaceutical's EBIT registered a high of $276.9 million during Q2 2025, and its lowest value of -$65.9 million during Q4 2021.
  • Over the past 5 years, Biomarin Pharmaceutical's median EBIT value was $39.2 million (recorded in 2022), while the average stood at $63.3 million.
  • In the last 5 years, Biomarin Pharmaceutical's EBIT surged by 136292.93% in 2023 and then tumbled by 14099.64% in 2025.
  • Biomarin Pharmaceutical's EBIT (Quarter) stood at -$65.9 million in 2021, then surged by 80.13% to -$13.1 million in 2022, then soared by 308.43% to $27.3 million in 2023, then skyrocketed by 491.69% to $161.4 million in 2024, then tumbled by 128.93% to -$46.7 million in 2025.
  • Its last three reported values are -$46.7 million in Q3 2025, $276.9 million for Q2 2025, and $223.9 million during Q1 2025.